ScholarWorks@Korea University: Kim, In San

Detailed Information

Kim, In San (김인산)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Drug delivery:4||Phagocytosis:4||Exosome:4||cancer immunotherapy:3||Macrophage:3||Extracellular vesicle:3||Doxorubicin:3||Atherosclerosis:3||Immune checkpoint blockade:3||exosomes:3||ferritin:3||CD47:3||immunotherapy:3||Stabilin2:3||Cancer immunotherapy:3||Active targeting:2||Cancer:2||extracellular vesicles:2||Ferritin nanocages:2||sepsis:2||SARSCoV2:2||COVID19:2||Apoptosis:2||efferocytosis:2||immune checkpoint blockade:2||Immunogenic cell death:2||Exosomes:2||Tumor necrosis factorrelated apoptosisinducing ligand (TRAIL):2||Immunotherapy:2||Nanocarrier:2||PD1:2||Muscle regeneration:2||siRNA delivery:2||PDL1:2||cytokine storm:1||NFkappa B signaling:1||placenta:1||Tumortargeted imaging:1||Transforming growth factor betainduced protein:1||Nanodrug delivery:1||Immunoadjuvant:1||Phosphatidylinositol4,5bisphosphate:1||Phagosome maturation:1||stabilin1:1||stabilin2:1||fusion:1||t lymphocytes:1||Nanocages:1||CD47 blockade:1||doxorubicin:1||Nanomedicine:1||myoblasts:1||Xkrelated protein 8:1||Solgel transition:1||Photodynamic therapy:1||tongue cancer:1||Bioengineering:1||Myoblast fusion:1||Paclitaxel:1||Stem cells:1||MSS colorectal Cancer:1||colloidal dispersion:1||PDL blockade:1||Mechanosensation:1||Mechanomodulation of immune response:1||HydroxymethylglutarylCoA reductase inhibitors:1||Activatable probe:1||Phage display:1||Tcell activity:1||immune response:1||Macrophages:1||Biomimetic delivery platform:1||Trimeric structure:1||STAB1:1||vascular integrity:1||cancer therapies:1||Membrane protein therapeutics:1||Nanoparticle:1||intrinsic anticancer vaccination:1||Imaging:1||Halflife:1||apoptosis:1||Prodrug:1||The multilayer nanoparticles:1||Docetaxel:1||Doxorubicininduced apoptosistargeted:1||chemotherapy:1||The composite nanoparticles:1||Peptide:1||Protein Nanocage:1||Adoptive cell transfer:1||cancerassociated fibroblast:1||Hypoxia:1||EV application:1||cancer therapeutics:1||Cytokine:1||E.coliderived monophosphoryl lipid A:1||Rac1 activity:1||mTOR pathway:1||Signal regulatory protein alpha:1||Alzheimer's disease mouse model:1||Small peptide:1||Proapoptotic peptide:1||Targeted therapy:1||extracellular vesicle:1||Multivalent hostguest chemistry:1||Nanovesicles:1||Myogenesis:1||Hyaluronic acid:1||Nanoparticles:1||tumor microenvironment:1||M2 macrophage:1||Protein nanocage:1||EVs:1||sEVs:1||EV engineering:1||proteinRNAbioconjugate:1||Bioorthogonal click chemistry:1||characterization and clinicalgrade exosomes:1||SETD6:1||double knockout:1||CD47mediated endocytosis:1||caspases:1||target therapies:1||Microplasmin:1||Intrinsically disordered protein:1||metronomic therapy:1||oral chemotherapy:1||radiationinduced apoptosistargeted chemotherapy:1||nanoplatform:1||lymphatic endothelial cells:1||Caspase3:1||Heparin:1||breast cancer:1||nanoparticles:1||Tumorspecific apoptosis:1||Immune suppressive effects:1||hypoxia:1||variants:1||Nuclear transport:1||Nuclear mechanics:1||Anticancer drug combinations:1||Head and neck neoplasms:1||Gulp1:1||osteoclast:1||large scale production:1||EV purification:1||clinical trial:1||Adoptive Tcell therapy:1||Tcell tracking:1||Stabilin1:1||hemorrhage:1||Acetylation inhibitory peptide:1||hyaluronidase:1||pancreatic cancer:1||Dendritic cells:1||phagocytosis:1||bystander killing effects:1||prodrugs:1||cancer therapy:1||GPIanchored proteins:1||PH20:1||scramblase:1||mutY DNA GLYCOSYLASE (MYH):1||TUMOR NECROSIS FACTOR ALPHA (TNFalpha):1||lymph node metastasis:1||Functionalization:1||Brain:1||Doxorubicin prodrug:1||ELISA:1||Core/shell nanoparticles:1||PCgla:1||Rhokinase (ROCK):1||Canceractivated prodrug:1||cancer:1||protein nanocage:1||SIRP?:1||STAT6:1||dendritic cells:1||drug therapy:1||combination:1||Cisdiamminedichloroplatinum (II):1||deficiency:1||Extracellular vesicles:1||Cancer therapeutics:1||decidua:1||TLR4 agonist:1||dendritic cell:1||hyaluronan:1||phosphatidylserine:1||SIRP alpha:1||Pharmacokinetics:1||B16F10 melanoma:1||NECROPTOSIS:1||viral fusogen:1||Deep penetration:1||In vivo imaging:1||Bladder tumor:1||diagnosis:1||Cyclodextrin:1||SPION:1||Radiotherapy:1||Gold nanoparticles:1||TRAP:1||Caspasecleavable peptidedoxorubicin conjugate:1||Nanocage therapeutics:1||simvastatin:1||Immune cell:1||multivalent vaccine:1||CD8positive Tlymphocytes:1||17 betaestradiol:1||Virus like particle:1||exosome:1||RNA interference:1||Bioactive molecules:1||Macrophagemediated phagocytosis of tumor cells:1||Signalregulatory protein alpha (SIRPα):1||Sepsis:1||Dendrimer:1||Peptides:1||Inflammation:1||IL10:1||ArhGAP12:1||Efferocytosis:1||Cancer cell:1||Stability:1||Ferritin:1||Clot targeting peptide:1||immunogenic cell death:1||Protein therapeutics:1||drug delivery system:1||differentiation:1||polyelectrolyte carrier:1||TUMOR NECROSIS FACTOR RECEPTOR TYPE 1ASSOCIATED DEATH DOMAIN (TRADD):1||tumor biomarker:1||Proteinbased nanocage:1||Multistage nanostructure:1||Phosphatidylserine:1||Combination therapy:1||tumor microenvironment (TME):1||Immunotherapy combination:1||Nanocage:1||Vaccine:1||Cancer vaccine:1||RBChitchhiking:1||in vivo imaging:1||Antigen presenting cell:1||Antitumer immunity:1||Thrombolysis:1||nanocages:1||therapeutics:1||Membrane protein:1||Microdomain:1||targeted therapy:1||membrane protein:1||Pluronic nanoparticles:1||Cancer therapy:1||Chemotherapy:1||Magneticguided drug delivery:1||Resensitization:1||Resistance:1||ROCK inhibitors:1||CD47 antagonist:1||oral delivery:1||oxaliplatin:1||Surface engineering:1||Tumordraining lymph node:1||Anticancer immune response:1||Immune checkpoint inhibitor:1||antigen presentation:1||adaptor protein:1||Tumor microenvironment:1||

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE